Venetoclax for Chronic Lymphocytic Leukaemia Progressing after Ibrutinib: a Multicentre, Open-Label Phase 2 Trial

BACKGROUND: Therapy targeting Bruton’s tyrosine kinase (BTK) with ibrutinib has transformed treatment for chronic lymphocytic leukaemia (CLL). Patients who are refractory or relapse after ibrutinib experience poor outcomes. Venetoclax is a selective, orally bioavailable inhibitor of BCL-2 that has a...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Lancet Oncol
Egile Nagusiak: Jones, Jeffrey A., Mato, Anthony R., Wierda, William G., Davids, Matthew S., Choi, Michael, Cheson, Bruce D., Furman, Richard R., Lamanna, Nicole, Barr, Paul M., Zhou, Lang, Chyla, Brenda, Salem, Ahmed Hamed, Verdugo, Maria, Humerickhouse, Rod A., Potluri, Jalaja, Coutre, Steven, Woyach, Jennifer, Byrd, John C.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2017
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6027999/
https://ncbi.nlm.nih.gov/pubmed/29246803
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30909-9
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak